
| ASSET | YEAR | % RETURN |
|---|---|---|
Azitra (AZTR) | 2023 | 3,285,614.29% |
Soleno Therapeutics (SLNO) | 2023 | 1,825.84% |
MoonLake Immunotherapeutics (MLTX) | 2023 | 469.72% |
Olema Pharmaceuticals (OLMA) | 2023 | 465.73% |
BridgeBio Pharma (BBIO) | 2023 | 418.89% |
Gyre Therapeutics (GYRE) | 2023 | 385.37% |
Sera Prognostics (SERA) | 2023 | 349.62% |
Immunome (IMNM) | 2023 | 345.83% |
Applied Therapeutics (APLT) | 2023 | 344.3% |
CASI Pharmaceuticals (CASI) | 2023 | 306.82% |
Minerva Neurosciences (NERV) | 2023 | 284.38% |
Tempest Therapeutics (TPST) | 2023 | 269.75% |
Tscan Therapeutics (TCRX) | 2023 | 253.33% |
Disc Medicine (IRON) | 2023 | 222.68% |
Autolus Therapeutics (AUTL) | 2023 | 222% |
MiMedx (MDXG) | 2023 | 210.99% |
Savara (SVRA) | 2023 | 209.21% |
Biohaven Pharmaceutical (BHVN) | 2023 | 204.63% |
Shattuck Labs (STTK) | 2023 | 200.84% |
Lunai Bioworks (LNAI) | 2023 | 199.06% |
Mereo BioPharma Group PLC ADR (MREO) | 2023 | 197.3% |
Immix Biopharma (IMMX) | 2023 | 194.47% |
Journey Medical (DERM) | 2023 | 174.29% |
Structure Therapeutics Inc American Depositary Shares (GPCR) | 2023 | 171.73% |
Cibus Global LLC (CBUS) | 2023 | 165.41% |